<?xml version='1.0' encoding='utf-8'?>
<document id="24889062"><sentence text="Auto-induction of phase I and phase II metabolism of artemisinin in healthy Chinese subjects after oral administration of a new artemisinin-piperaquine fixed combination."><entity charOffset="53-64" id="DDI-PubMed.24889062.s1.e0" text="artemisinin" /><entity charOffset="128-139" id="DDI-PubMed.24889062.s1.e1" text="artemisinin" /><entity charOffset="140-151" id="DDI-PubMed.24889062.s1.e2" text="piperaquine" /><pair ddi="false" e1="DDI-PubMed.24889062.s1.e0" e2="DDI-PubMed.24889062.s1.e0" /><pair ddi="false" e1="DDI-PubMed.24889062.s1.e0" e2="DDI-PubMed.24889062.s1.e1" /><pair ddi="false" e1="DDI-PubMed.24889062.s1.e0" e2="DDI-PubMed.24889062.s1.e2" /><pair ddi="false" e1="DDI-PubMed.24889062.s1.e1" e2="DDI-PubMed.24889062.s1.e1" /><pair ddi="false" e1="DDI-PubMed.24889062.s1.e1" e2="DDI-PubMed.24889062.s1.e2" /></sentence><sentence text="Artequick is a relatively inexpensive artemisinin (Qing-hao-su; QHS)-based combination therapy (ACT) that contains QHS and piperaquine (PQ), which has not been widely used because of the decreased concentration level of QHS after repeated oral administrations for five to seven days as a monotherapy"><entity charOffset="38-49" id="DDI-PubMed.24889062.s2.e0" text="artemisinin" /><entity charOffset="123-134" id="DDI-PubMed.24889062.s2.e1" text="piperaquine" /><entity charOffset="136-138" id="DDI-PubMed.24889062.s2.e2" text="PQ" /><pair ddi="false" e1="DDI-PubMed.24889062.s2.e0" e2="DDI-PubMed.24889062.s2.e0" /><pair ddi="false" e1="DDI-PubMed.24889062.s2.e0" e2="DDI-PubMed.24889062.s2.e1" /><pair ddi="false" e1="DDI-PubMed.24889062.s2.e0" e2="DDI-PubMed.24889062.s2.e2" /><pair ddi="false" e1="DDI-PubMed.24889062.s2.e1" e2="DDI-PubMed.24889062.s2.e1" /><pair ddi="false" e1="DDI-PubMed.24889062.s2.e1" e2="DDI-PubMed.24889062.s2.e2" /></sentence><sentence text=" This study was designed to evaluate the potential auto-induction metabolism of QHS in healthy Chinese adults after a two-day oral administration of QHS-PQ"><entity charOffset="153-154" id="DDI-PubMed.24889062.s3.e0" text="PQ" /></sentence><sentence text=" The effect of QHS-PQ on the activity of the CYP2B6 and CYP3A4 was also investigated"><entity charOffset="19-20" id="DDI-PubMed.24889062.s4.e0" text="PQ" /></sentence><sentence text="" /><sentence text="Fourteen healthy Chinese subjects received two-day oral doses of QHS-PQ (Artequick)"><entity charOffset="65-71" id="DDI-PubMed.24889062.s6.e0" text="QHS-PQ" /><entity charOffset="69-74" id="DDI-PubMed.24889062.s6.e1" text="PQ" /><pair ddi="false" e1="DDI-PubMed.24889062.s6.e0" e2="DDI-PubMed.24889062.s6.e0" /><pair ddi="false" e1="DDI-PubMed.24889062.s6.e0" e2="DDI-PubMed.24889062.s6.e1" /></sentence><sentence text=" A two-drug cocktail consisting of bupropion and midazolam was used to assess the activities of CYP2B6 and CYP3A, respectively"><entity charOffset="35-44" id="DDI-PubMed.24889062.s7.e0" text="bupropion" /><entity charOffset="49-58" id="DDI-PubMed.24889062.s7.e1" text="midazolam" /><pair ddi="false" e1="DDI-PubMed.24889062.s7.e0" e2="DDI-PubMed.24889062.s7.e0" /><pair ddi="false" e1="DDI-PubMed.24889062.s7.e0" e2="DDI-PubMed.24889062.s7.e1" /></sentence><sentence text=" Plasma samples were analysed for QHS and its phase I/II metabolites, probe drugs and their metabolites, using a validated liquid chromatography tandem mass spectrometric (LC-MS) method" /><sentence text="" /><sentence text="Four major phase I metabolites of QHS (M1-M3 and deoxy-QHS) and two subsequent phase II metabolites (M4-M5) were detected in human plasma after oral administrations of QHS-PQ"><entity charOffset="172-180" id="DDI-PubMed.24889062.s10.e0" text="PQ" /></sentence><sentence text=" The AUC0-t of the QHS and its phase I metabolites decreased significantly (P &lt; 0" /><sentence text="05) with increased oral clearance (CL/F) after two-day oral doses of QHS-PQ, whereas its phase II metabolites exhibited higher AUC (P &lt; 0"><entity charOffset="69-75" id="DDI-PubMed.24889062.s12.e0" text="QHS-PQ" /><entity charOffset="73-78" id="DDI-PubMed.24889062.s12.e1" text="PQ" /><pair ddi="false" e1="DDI-PubMed.24889062.s12.e0" e2="DDI-PubMed.24889062.s12.e0" /><pair ddi="false" e1="DDI-PubMed.24889062.s12.e0" e2="DDI-PubMed.24889062.s12.e1" /></sentence><sentence text="01)" /><sentence text=" The phase I metabolic capability, calculated by the AUC0-t ratio of all phase I metabolites to QHS, increased 1" /><sentence text="5-fold after the repeated dose (P &lt; 0" /><sentence text="01), and the phase II metabolic capability increased 1" /><sentence text="5-fold for M4 and 3" /><sentence text="0-fold for M5" /><sentence text=" The enzyme activity of CYP2B6 and CYP3A4 increased 2" /><sentence text="1-fold and 3" /><sentence text="2-fold, respectively, after two-day oral doses of QHS-PQ"><entity charOffset="54-55" id="DDI-PubMed.24889062.s21.e0" text="PQ" /></sentence><sentence text="" /><sentence text="The auto-induction of both phase I and phase II metabolism of QHS was present in healthy Chinese subjects after a recommended two-day oral dose of QHS-PQ"><entity charOffset="151-152" id="DDI-PubMed.24889062.s23.e0" text="PQ" /></sentence><sentence text=" The auto-induction metabolism also existed for phase I metabolites of QHS" /><sentence text=" The enzyme activity of CYP2B6 and CYP3A4 was induced after the two-day oral doses of QHS-PQ"><entity charOffset="90-91" id="DDI-PubMed.24889062.s25.e0" text="PQ" /></sentence><sentence text=" Based on these results, the alternative common three-day regimen for QHS-PQ could probably lead to lower bioavailability of QHS and higher potential of drug-drug interaction caused by the induction of drug-metabolizing enzymes"><entity charOffset="74-75" id="DDI-PubMed.24889062.s26.e0" text="PQ" /></sentence><sentence text="" /></document>